Erythropoiesis-stimulating agents (ESAs) are first-line therapy to treat anemia in patients with LR-MDS with serum erythropoietin (EPO) levels ≤500 U/l and low transfusion burden [2, 5]. The gene discussed is EPO; the disease is anemia (phenotype).